Breaking News, Collaborations & Alliances

Chime Biologics, MedPacto Partner to Accelerate Biologics Development & Manufacturing

Aims to streamline the process from tech transfer to cGMP clinical manufacturing for IND submissions.

Author Image

By: Charlie Sternberg

Associate Editor

Chime Biologics, a global CDMO, has announced a strategic collaboration with MedPacto, a South Korean clinically staged company.   MedPacto, known for its focus on cancer therapeutics, will leverage Chime Biologics’ expertise in biologics development to streamline the process from tech transfer to cGMP clinical manufacturing for Investigational New Drug (IND) submissions. Under the agreement, Chime Biologics will advance the Chemistry, Manufacturing, and Controls (CMC) process developmen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters